Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Mirati Therapeutics Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07415031CT.gov A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies | — | Recruiting | — | — | — |
NCT07432295CT.gov Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | — | Recruiting | — | — | — |
NCT06818812CT.gov A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | — | Active Not Recruiting | — | — | — |
NCT06967155CT.gov A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT06761417CT.gov A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults | — | Recruiting | — | — | — |
NCT06621563CT.gov Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06632262CT.gov A Phase 2 Clinical Study of ABSK061 and ABSK043 | — | Recruiting | — | — | — |
NCT06576037CT.gov Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin | — | Recruiting | — | — | — |
NCT06625775CT.gov Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06504732CT.gov To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer | — | Recruiting | — | — | — |
Show 40 more trialsShow fewer
NCT06275958CT.gov DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT06179160CT.gov A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | — | Recruiting | — | — | — |
NCT06041035CT.gov A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05954078CT.gov Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer | — | Recruiting | — | — | — |
NCT05836324CT.gov A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05919264CT.gov FOG-001 in Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05382559CT.gov A Study of ASP3082 in Adults With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05346484CT.gov A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05186558CT.gov Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL | — | Unknown | — | — | — |
NCT04607421CT.gov A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04522284CT.gov PRECISE CURATE.AI Pilot Clinical Trial | — | Unknown | — | — | — |
NCT04802980CT.gov A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor | — | Unknown | — | — | — |
NCT04080843CT.gov Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients | — | Completed | — | — | — |
NCT03775525CT.gov Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer | — | Unknown | — | — | — |
NCT03823989CT.gov Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients | — | Completed | — | — | — |
NCT03781362CT.gov Study of CPI-100 in Patients With Advanced Tumors | — | Completed | — | — | — |
NCT03641547CT.gov M6620 Plus Standard Treatment in Oesophageal and Other Cancer | — | Completed | — | — | — |
NCT03503604CT.gov A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | — | Unknown | — | — | — |
NCT03314935CT.gov A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT02943733CT.gov Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs | — | Terminated | — | — | — |
NCT03250832CT.gov Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03085914CT.gov A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) | — | Completed | — | — | — |
NCT02861300CT.gov CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | — | Completed | — | — | — |
NCT02720068CT.gov Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) | — | Completed | — | — | — |
NCT02715531CT.gov A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | — | Completed | — | — | — |
NCT02648711CT.gov Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02435927CT.gov ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin | — | Unknown | — | — | — |
NCT02178722CT.gov Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | — | Completed | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01867879CT.gov Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01705002CT.gov Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. | — | Completed | — | — | — |
NCT01522989CT.gov PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies | — | Unknown | — | — | — |
NCT01362374CT.gov Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01327612CT.gov Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | — | Completed | — | — | — |
NCT00920868CT.gov XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | — | Completed | — | — | — |
NCT00811993CT.gov A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT00207129CT.gov Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies | — | Completed | — | — | — |
NCT02494596CT.gov A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00052273CT.gov LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02354612CT.gov Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxaliplatin (this asset) | Mirati Therapeutics Inc. | P3 | B · 59 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Oxaliplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 76 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
| Colorectal Neoplasm | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxaliplatin in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxaliplatin-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →